Egetis Therapeutics AB (publ) (STO:EGTX)

Sweden · Delayed Price · Currency is SEK

7.77

-0.12 (-1.52%)

Sep 2, 2026, 5:29 PM CET

Egetis Therapeutics AB Financials Overview

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	66	62.4	46.1	57.6	22.6	38.2
Revenue Growth	39.53%	35.36%	-19.96%	154.87%	-40.84%	-6.05%
Gross Profit	11	12.4	34.5	46.6	-120	-58.4
Operating Income	-389.1	-330	-321.8	-311.3	-197	-105.2
Net Income	-405.4	-342.5	-343.6	-326.9	-193.8	-104.5
Earnings Per Share	-1.01	-0.93	-1.12	-1.30	-1.00	-0.60
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Emcitate	66	62.3	46.1	57.6	21.9	15.7
Aladote	-	0.1	-	-	-	-
Total	66	62.4	46.1	57.6	22.5	38.3

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	378.4	215.8	351	303.3	127.7	144
Total Debt	68.8	85	117.1	113	2.7	4.2
Net Cash (Debt)	309.6	130.8	233.9	190.3	125	139.8
Net Cash Growth	192.63%	-44.08%	22.91%	52.24%	-10.59%	-50.63%
Net Cash Per Share	0.77	0.35	0.75	0.73	0.64	0.78

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-300.1	-267	-227.9	-278.4	-173.5	-130.1
Capital Expenditures	0.5	-	-	-	-	-0.2
Free Cash Flow	-299.6	-267	-227.9	-278.4	-173.5	-130.3
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	16.67%	19.87%	74.84%	80.90%	-	-152.88%
Operating Margin	-589.55%	-528.85%	-698.05%	-540.45%	-871.68%	-275.39%
Pretax Margin	-613.64%	-548.24%	-744.69%	-567.36%	-857.52%	-273.56%
Profit Margin	-614.24%	-548.88%	-745.34%	-567.53%	-857.52%	-273.56%
FCF Margin	-453.94%	-427.89%	-494.36%	-483.33%	-767.70%	-341.10%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	491.13	22.61	5.66	5.66	5.66	5.66
PS Ratio	55.58	33.82	54.55	28.34	67.42	29.00